Kamada closed the most recent trading day at $5.67, moving -1.05% from the previous trading session. This change was narrower than the S&P 500's 1.65% loss on the day. Meanwhile, the Dow lost 1.79%, and the Nasdaq, a tech-heavy index, lost 1.96%.
Coming into today, shares of the biopharmaceutical had lost 4.98% in the past month. In that same time, the Medical sector lost 2.16%, while the S&P 500 gained 1.53%.
KMDA will be looking to display strength as it nears its next earnings release. On that day, KMDA is projected to report earnings of $0.05 per share, which would represent year-over-year growth of 66.67%. Our most recent consensus estimate is calling for quarterly revenue of $22.87 million, up 31.14% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.47 per share and revenue of $126.91 million, which would represent changes of -17.54% and +10.87%, respectively, from the prior year.
Any recent changes to analyst estimates for KMDA should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. KMDA is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, KMDA is currently trading at a Forward P/E ratio of 12.28. Its industry sports an average Forward P/E of 24.41, so we one might conclude that KMDA is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 72, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow KMDA in the coming trading sessions, be sure to utilize Zacks.com.
Image: Bigstock
Kamada (KMDA) Stock Moves -1.05%: What You Should Know
Kamada closed the most recent trading day at $5.67, moving -1.05% from the previous trading session. This change was narrower than the S&P 500's 1.65% loss on the day. Meanwhile, the Dow lost 1.79%, and the Nasdaq, a tech-heavy index, lost 1.96%.
Coming into today, shares of the biopharmaceutical had lost 4.98% in the past month. In that same time, the Medical sector lost 2.16%, while the S&P 500 gained 1.53%.
KMDA will be looking to display strength as it nears its next earnings release. On that day, KMDA is projected to report earnings of $0.05 per share, which would represent year-over-year growth of 66.67%. Our most recent consensus estimate is calling for quarterly revenue of $22.87 million, up 31.14% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.47 per share and revenue of $126.91 million, which would represent changes of -17.54% and +10.87%, respectively, from the prior year.
Any recent changes to analyst estimates for KMDA should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. KMDA is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, KMDA is currently trading at a Forward P/E ratio of 12.28. Its industry sports an average Forward P/E of 24.41, so we one might conclude that KMDA is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 72, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow KMDA in the coming trading sessions, be sure to utilize Zacks.com.